Deep Vein Thrombosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Deep Vein Thrombosis stocks.

Deep Vein Thrombosis Stocks Recent News

Date Stock Title
Apr 25 SNY AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Apr 25 SNY Sanofi 2024 Q1 - Results - Earnings Call Presentation
Apr 25 SNY 20 Fastest Growing Health Tech Companies in the World
Apr 25 SNY Sanofi (SNY) Q1 2024 Earnings Call Transcript
Apr 25 SNY Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Apr 25 SNY AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
Apr 25 SNY US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Apr 25 SNY Sanofi Sales, Profit Beat Expectations
Apr 25 SNY UPDATE 2-Sanofi profit slips on generic competition and currency effects
Apr 25 SNY Sanofi Non-GAAP EPS of €1.78, revenue of €10.46B; reaffirms FY24 business EPS guidance
Apr 25 SNY Sanofi profit slips on generic competition and currency effects
Apr 25 SNY Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Apr 24 SNY What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Apr 23 SNY Sanofi reportedly lining up banks for consumer products spinoff
Apr 23 SNY Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff
Apr 23 SNY Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Apr 23 SNY Sanofi succeeds in late-stage trial for blood disorder candidate
Apr 23 SNY Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Apr 22 SNY Sanofi reportedly settles 4K Zantac cases for $100M
Apr 22 SNY Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer
Deep Vein Thrombosis

Deep vein thrombosis (DVT), is the formation of a blood clot in a deep vein, most commonly the legs. Symptoms may include pain, swelling, redness, or warmth of the affected area. About half of cases have no symptoms. Complications may include pulmonary embolism, as a result of detachment of a clot which travels to the lungs, and post-thrombotic syndrome.Risk factors include recent surgery, cancer, trauma, lack of movement, obesity, smoking, hormonal birth control, pregnancy and the period following birth, antiphospholipid syndrome, and certain genetic conditions. Genetic factors include deficiencies of antithrombin, protein C, and protein S, and factor V Leiden mutation. The underlying mechanism typically involves some combination of decreased blood flow rate, increased tendency to clot, and injury to the blood vessel wall.Individuals suspected of having DVT may be assessed using a clinical prediction rule such as the Wells score. A D-dimer test may also be used to assist with excluding the diagnosis or to signal a need for further testing. Diagnosis is most commonly confirmed by ultrasound of the suspected veins. Together, DVT and pulmonary embolism are known as venous thromboembolism (VTE).Anticoagulation (blood thinners) is the standard treatment. Typical medications include low-molecular-weight heparin, warfarin, or a direct oral anticoagulant. Wearing graduated compression stockings may reduce the risk of post-thrombotic syndrome. Prevention may include early and frequent walking, calf exercises, aspirin, anticoagulants, graduated compression stockings, or intermittent pneumatic compression. The rate of DVTs increases from childhood to old age; in adulthood, about one in 1000 adults are affected per year. About 5% of people are affected by a VTE at some point in time.

Browse All Tags